MA28104A1 - Sel antagonistes de ccr-2 - Google Patents

Sel antagonistes de ccr-2

Info

Publication number
MA28104A1
MA28104A1 MA28957A MA28957A MA28104A1 MA 28104 A1 MA28104 A1 MA 28104A1 MA 28957 A MA28957 A MA 28957A MA 28957 A MA28957 A MA 28957A MA 28104 A1 MA28104 A1 MA 28104A1
Authority
MA
Morocco
Prior art keywords
salt
ccr
antagonists
succinate salt
methoxytetrahydro
Prior art date
Application number
MA28957A
Other languages
English (en)
Inventor
Mark Jensen
Robert Larsen
Daniel Richard Sidler
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of MA28104A1 publication Critical patent/MA28104A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention fournit une synthèse efficace pour la préparation de ((1R,3S)-3-isopropyl-3-{[3-(trifluorométhyl)-7,8-dihydro-1,6-naphtyridin-6(5H)-yl] carbonyl} cyclopentyl) [(3S,4S)-3-méthoxytétrahydro-2H-pyran-4-yl] aminé et son sel succinate. La présente invention fournit en plus une synthèse efficace pour la préparation des intermédiaires (3R)-3-méthoxytétrahydro-4H-pyran-4-one; acide (1S,4S)-4-(2,5-diméthyl- 1H-pyrrol- 1-yl)-1-isopropylcyclopent-2-ene-1-carboxylique; et 3-(trifluorométhyl)-5,6,7,8-tétrahydro-1,6-naphtydirine; et pour la préparation du précurseur (3S,4S)-N-((1S,4S)-4-isopropyl-4-{[3-(trifluorométhyl)-7,8-dihydro-1,6-naphtyridin-6(5H)-yl] carbonyl} cyclopent-2-en-1-yl)-3-méthoxytétrahydro-2H-pyran-4-amine. L'invention concerne en outre les propriétés supérieures du sel succinate de ((1R,3S)-3-isopropyl-3-{[3-(trifiuorométhyl)-7,8-dihydro-1,6-naphtyridin-6(5H)-yl]carbonyl}cyclopentyl) [(3S,4S)-3-méthoxytétrahydro-2H-pyran-4-yl] aminé.
MA28957A 2003-10-27 2006-04-24 Sel antagonistes de ccr-2 MA28104A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51473503P 2003-10-27 2003-10-27

Publications (1)

Publication Number Publication Date
MA28104A1 true MA28104A1 (fr) 2006-08-01

Family

ID=34572774

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28957A MA28104A1 (fr) 2003-10-27 2006-04-24 Sel antagonistes de ccr-2

Country Status (21)

Country Link
US (1) US7473696B2 (fr)
EP (1) EP1682135B1 (fr)
JP (1) JP4542550B2 (fr)
KR (1) KR20060101476A (fr)
CN (1) CN1870998B (fr)
AT (1) ATE517622T1 (fr)
AU (1) AU2004287416C1 (fr)
BR (1) BRPI0415836A (fr)
CA (1) CA2543201C (fr)
CO (1) CO5690606A2 (fr)
EC (1) ECSP066524A (fr)
IL (1) IL175009A0 (fr)
IS (1) IS8400A (fr)
MA (1) MA28104A1 (fr)
MX (1) MXPA06004647A (fr)
NO (1) NO20062377L (fr)
NZ (1) NZ546447A (fr)
RU (1) RU2317295C1 (fr)
UA (1) UA81365C2 (fr)
WO (1) WO2005044264A1 (fr)
ZA (1) ZA200602752B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2479B1 (en) 2002-04-29 2009-01-20 ميرك شارب اند دوم ليمتد Rates for the activity of the chemokine receptor of tetrahydrobranyl cycloneptil tetrahydrobredo predine
US20060030582A1 (en) * 2002-04-29 2006-02-09 Demartino Julie Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
GEP20115290B (en) 2002-11-27 2011-09-26 Incyte Corp 3-aminopyrrolidine derivatives as modulators of chemokine receptors
US7393844B2 (en) * 2003-03-18 2008-07-01 Merck & Co., Inc. Tetrahydropyranyl cyclopentyl heterocyclic amide modulators of chemokine receptor activity
AR045875A1 (es) * 2003-10-27 2005-11-16 Merck & Co Inc Procedimiento para la preparacion del antagonista ccr-2
DK1696919T3 (da) 2003-12-18 2013-12-09 Incyte Corp 3-cycloalkylaminopyrrolidin-derivater som modulatorer af chemokinreceptorer
CN1950085A (zh) 2004-05-11 2007-04-18 因赛特公司 作为趋化因子受体调节剂的3－(4－杂芳基环己基氨基)环戊烷羧酰胺
GB0413605D0 (en) * 2004-06-17 2004-07-21 Addex Pharmaceuticals Sa Novel compounds
GEP20094843B (en) 2004-06-28 2009-11-25 Incyte Corp 3-aminocyclopentane carboxamides as modulators of chemokine receptors
UA83311C2 (en) 2004-06-28 2008-06-25 Инсайт Корпорейшн 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
US8754107B2 (en) 2006-11-17 2014-06-17 Abbvie Inc. Aminopyrrolidines as chemokine receptor antagonists
US20090076065A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched mk-0812
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
WO2012125663A2 (fr) * 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Dérivés d'amino cyclopentane substitués par cyclohexane en tant qu'antagonistes utiles de ccr2
WO2013149376A1 (fr) 2012-04-02 2013-10-10 Abbott Laboratories Antagonistes de récepteurs de chimiokines
JP2014193854A (ja) * 2013-02-28 2014-10-09 Santen Pharmaceut Co Ltd テトラヒドロピラニルアミノシクロペンチルカルボニルテトラヒドロピリドピリジン誘導体を有効成分として含有する後眼部疾患の予防または治療剤
EP3297438B1 (fr) 2015-05-21 2021-10-20 ChemoCentryx, Inc. Modulateurs du ccr2
JP7453139B2 (ja) 2017-09-25 2024-03-19 ケモセントリックス，インコーポレイティド ケモカイン受容体２（ｃｃｒ２）アンタゴニスト及びｐｄ－１／ｐｄ－ｌ１阻害剤を使用した併用療法
JP7442141B2 (ja) 2018-01-08 2024-03-04 ケモセントリックス，インコーポレイティド Ｃｃｒ２アンタゴニストによる固形腫瘍の治療方法
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
CN112341350A (zh) * 2020-10-19 2021-02-09 江苏威奇达药业有限公司 酶法拆分γ-内酰胺后副产物的处理方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9417249D0 (en) * 1994-08-26 1994-10-19 Wellcome Found A novel salt
JPH09291034A (ja) * 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
FR2787790A3 (fr) * 1998-12-23 2000-06-30 Sanofi Sa Procede de preparation du (r)-(+)-3-{1°2-(4-benzoyl-2-(3,4- difluorophenyl)morpholin-2-yl)ethyl!-4-phenylpiperidin-4-yl} -1,1-dimethyluree, de ses sels, solvats et/ou hydrates
WO2000076512A1 (fr) 1999-06-11 2000-12-21 Merck & Co., Inc. Modulateurs cyclopentyliques de l'activite du recepteur de la chimiokine
JP2004506013A (ja) 2000-08-17 2004-02-26 メルク　エンド　カムパニー　インコーポレーテッド シクロペンチル系ケモカイン受容体活性調節剤
NZ525788A (en) * 2000-11-28 2004-11-26 Pfizer Prod Inc Salts of a isothiazole-4-carboxamide and their use as anti-hyperproliferation agents
DE60209929T2 (de) * 2001-11-29 2006-11-16 Pfizer Products Inc., Groton Succinatsalze von 58;8;14-triatetracyclo[10.3.1.0 2,11 .0 4,9]-hexadeca-2,11,3,5,7,9,-pentaen und pharmazeutische zusammensetzungen
UA75482C2 (en) * 2001-12-12 2006-04-17 Pfizer Prod Inc Salts of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methylpyridine-3-yloxy)phenylamino]quinozaline -6-yl}alyl)acetamide, a method for the preparation and use thereof for the treatment of cancer
JO2479B1 (en) 2002-04-29 2009-01-20 ميرك شارب اند دوم ليمتد Rates for the activity of the chemokine receptor of tetrahydrobranyl cycloneptil tetrahydrobredo predine
ATE396993T1 (de) * 2002-04-29 2008-06-15 Merck & Co Inc Tetrahydropyranyl-cyclopentyl- tetrahydropyridopyridin-modulatoren der chemokin- rezeptor-aktivität
US7166614B2 (en) * 2002-04-29 2007-01-23 Merck & Co., Inc. Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity
AR045875A1 (es) * 2003-10-27 2005-11-16 Merck & Co Inc Procedimiento para la preparacion del antagonista ccr-2

Also Published As

Publication number Publication date
CO5690606A2 (es) 2006-10-31
AU2004287416C1 (en) 2010-09-09
MXPA06004647A (es) 2006-06-27
US7473696B2 (en) 2009-01-06
AU2004287416A1 (en) 2005-05-19
IL175009A0 (en) 2006-08-20
JP2007509940A (ja) 2007-04-19
UA81365C2 (en) 2007-12-25
AU2004287416B2 (en) 2009-11-19
CA2543201C (fr) 2010-12-21
CA2543201A1 (fr) 2005-05-19
EP1682135A4 (fr) 2009-11-25
ZA200602752B (en) 2007-08-29
US20070135474A1 (en) 2007-06-14
EP1682135B1 (fr) 2011-07-27
RU2317295C1 (ru) 2008-02-20
CN1870998A (zh) 2006-11-29
IS8400A (is) 2006-04-06
CN1870998B (zh) 2010-10-20
NO20062377L (no) 2006-05-24
NZ546447A (en) 2009-02-28
BRPI0415836A (pt) 2007-01-02
WO2005044264A1 (fr) 2005-05-19
ATE517622T1 (de) 2011-08-15
KR20060101476A (ko) 2006-09-25
JP4542550B2 (ja) 2010-09-15
ECSP066524A (es) 2006-10-10
EP1682135A1 (fr) 2006-07-26

Similar Documents

Publication Publication Date Title
MA28104A1 (fr) Sel antagonistes de ccr-2
PA8637601A1 (es) Compuestos moduladores de la actividad de c-kit y usos de los mismos
WO2006034039A3 (fr) Morphinanes substitues et leurs procedes d'utilisation
BR0014352A (pt) Cetoenóis espirocìclicos substituìdos por trifluormetila
DE60312701D1 (de) Darstellung von 1h-imidazoä4,5-cüchinolin-4-aminen über neue 1h-imidazoä4,5-cüchinolin-4-cyano- und 1h-imidazoä4,5-cüchinolin-4-carboxamid intermediate
WO2007013896A3 (fr) Composes modulant l'activite de c-kit et c-fms et utilisations
WO2005037198A3 (fr) Preparation d'azabenzimidazoles 1,7-disubstitues comme inhibiteurs de kinases
HK1086494A1 (zh) 作為金屬蛋白酶抑制劑的氮雜螺烷衍生物
WO2001066534A3 (fr) Antagonistes du recepteur d'histamine-3 diamino cycliques et bicycliques
WO2005040169A3 (fr) Composes heterocycliques fusionnes
GEP20074210B (en) Tropane derivatives as ccr5 modulators
PL1730144T3 (pl) Podstawione pochodne 1,4,8-triazaspiro[4.5]dekan-2-onu
RU2009140095A (ru) Гетероарильные производные
WO2005058819A3 (fr) Formes polymorphiques de la base du tegaserod et des sels de celui-ci
WO2002012224A3 (fr) Composes bicycliques
MXPA05008183A (es) Proceso para preparar pirrolotriazina como inhibidores de cinasa.
WO2004106340A3 (fr) Derives substitues en 4 de pyrazolo[3,4-d]pyrimidine et pyrrolo[2,3-d]pyrimidine et utilisations associees
WO2005049561A3 (fr) Procedes de preparation d'un nouveau derive de bleu de methylene
WO2005044795A8 (fr) Procede d'elaboration d'antagoniste vis-a-vis du ccr-2
IS7492A (is) Lyfjablöndu uppskriftir, sem innifela melantónín
EP1786815A4 (fr) Composes spiro et procedes pour la modulation de l'activite de recepteur de chimiokine
MX2010001602A (es) "compuestos de 2-(2-oxoindolin-3-iliden)metil-5-(2-hidroxi-3-morfo lin-4-il-propil)-6,7-dihidro-1h-pirrol[3,2-c]pirridin-4(5h)-ona y su uso como inhibidores de proteína quinasa".
WO2006074919A3 (fr) Amides d'acide 3-amino-6-aryl-thieno[2,3-b]pyridine-2-carboxylique, preparations pharmaceutiques contenant ces composes et utilisation desdits composes comme inhibiteurs de la liberation de tnf$g(a)
EA200501829A1 (ru) Способ получения непептидных замещённых спиробензоазепиновых производных
HUP0103912A3 (en) Substituted alkylpyridazinone derivatives, process for their preparation, their use for the preparation of pharmaceutical compositions with anxiolytic activity